Maha Katabi, PhD, CFA

Maha Katabi, PhD, CFA

General Partner

Maha is an experienced investor with over two decades in managing public and private biotech companies through bull and bear markets. She is focused on investing in development stage biopharmaceuticals and is currently a member of the board of directors of Aerovate (AVTE), Quanta, RayzeBio, and Vera (VERA), and was recently a board member of Gyroscope (acquired by Novartis) and Amplyx (acquired by Pfizer).

Prior to joining Sofinnova in 2019, Maha co-invested with our team in multiple companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (TSRX-acquired by Cubist). Maha was Managing Partner of Oxalis Capital.  Prior to founding Oxalis, Maha was Partner at Sectoral Asset Management, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Additionally, she was a Portfolio Manager for a family of funds that invested in small cap healthcare companies. She started her career in venture as a principal investor with associate and principal roles at T2C2/Bio and Ventures West.

Maha received her B.Sc. In Biology and PhD in Pharmacology from McGill University, where she was a Cancer Research Society fellow, and is a CFA charter holder since 2011. She currently serves as Chair of the board of Exactis Innovation, a not-for profit oncology precision medicine network and has served on the Canadian Task Force for COVID-19 Therapeutics until February 2021.

Active Companies

Alumni Companies